Results 1 to 10 of about 12,053 (162)

Current perspectives on lipid management in diabetic kidney disease: Can fibrates offer advantages over statins for renal outcomes? [PDF]

Journal of Research in Medical Sciences
Diabetic kidney disease (DKD) affects 30%–40% of patients with diabetes mellitus (DM). Dyslipidemia is a key modifiable risk factor for the development and progression of DKD.
Mohammad Reza Chitsazi, Farzad Safari, Elena Malekpour, Seyed Arsham Mirzaei, Mohammad Hossein Shafieyoun, Faraz Golafshan, Hanieh Rouzbahani, Mohadese Nekookhoo, Ali Noursina, Mansour Siavash   +9 more
doaj   +2 more sources

Exploring the mechanism of fibrates regulating HIF-1A in the treatment of ischemic stroke based on network pharmacology and molecular docking [PDF]

BMC Research Notes
Fibrates can prevent and treat ischemic stroke (IS), the occurrence and development of IS is closely related to hypoxia-inducible factor-1A (HIF-1A). However, the exact mechanism by which fibrates regulate HIF-1A to treat IS remains unclear.
Fengjiao Yang, Zixuan Yang, Ya Yan, Yun Gu, Pengyu Wang, Min Wang, Jianjie Chen, Xiaoshan Du, Guangming Wang   +8 more
doaj   +2 more sources

Reduced Muscle Loss in Patients With NSCLC Taking Fibrates: Findings From a Retrospective Observational Study [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background The cancer‐anorexia‐cachexia syndrome (CACS) is a common and debilitating wasting disorder characterized by loss of skeletal muscle and worse morbidity and mortality.
Rahmi Elahjji, Tahj Blow, Rahul Grover, Maurice A. Hurd, Richard F. Dunne, Bette J. Caan, Elizabeth M. Cespedes Feliciano, Andrew J. Plodkowski, James H. Flory, Marcus D. Goncalves   +9 more
doaj   +2 more sources

Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases [PDF]

Frontiers in Pharmacology
IntroductionFibrates are effective triglyceride-lowering drugs, but they may affect bile acid metabolism, raising concerns about biliary adverse drug events (ADEs).ObjectiveIn this study, we used spontaneous reporting system databases to evaluate the ...
Satoko Watanabe, Kyosuke Nagura, Naoto Okada, Taro Watanabe, Taro Watanabe, Hidenori Sagara, Hidenori Sagara   +6 more
doaj   +2 more sources

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

Metabolites, 2023
Statins, the intestinal cholesterol transporter inhibitor (ezetimibe), and PCSK9 inhibitors can reduce serum LDL-C levels, leading to a significant reduction in cardiovascular events.
Shizuya Yamashita, Manfredi Rizzo, Ta-Chen Su, Daisaku Masuda   +3 more
doaj   +1 more source

Impact of concomitant fibrates on immunotherapy outcomes for advanced non‐small cell lung cancer

Cancer Medicine, 2023
Background Peroxisome proliferator‐activated receptor agonists such as fibrates restore oxidative metabolism in cytotoxic T‐lymphocytes, thereby enhancing response to immune checkpoint inhibitors (ICI) in preclinical models. However, there is no evidence
William A. Stokes, Madhusmita Behera, Renjian Jiang, David A. Gutman, Zhonglu Huang, Abigail Burns, Nikhil T. Sebastian, Vidula Sukhatme, Michael C. Lowe, Suresh S. Ramalingam, Vikas P. Sukhatme, Drew Moghanaki   +11 more
doaj   +1 more source

Association between triglyceride levels and cardiovascular disease in patients with acute pancreatitis. [PDF]

PLoS ONE, 2018
Conventional wisdom supports prescribing "fibrates before statins", that is, prioritizing treatment of hypertriglyceridemia (hTG) to prevent pancreatitis ahead of low-density lipoprotein cholesterol to prevent coronary heart disease.
Laurel A Copeland, C Scott Swendsen, Dawn M Sears, Andrea A MacCarthy, Catherine J McNeal   +4 more
doaj   +1 more source

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing

Annals of Medicine, 2022
Based on separate protective mechanisms related to lipid metabolism, viral cell entry and inflammation, fibrate treatment might be advantageous among patients who have been taking fibrates before SARS-CoV-2 infection and continue taking them during the ...
Alpo Vuorio, Jonas Brinck, Petri T. Kovanen   +2 more
doaj   +1 more source

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates

iScience, 2020
Summary: Most triacylglycerol-lowering fibrates have been developed in the 1960s–1980s before their molecular target, peroxisome proliferator-activated receptor alpha (PPARα), was identified.
Shotaro Kamata, Takuji Oyama, Kenta Saito, Akihiro Honda, Yume Yamamoto, Keisuke Suda, Ryo Ishikawa, Toshimasa Itoh, Yasuo Watanabe, Takahiro Shibata, Koji Uchida, Makoto Suematsu, Isao Ishii   +12 more
doaj   +1 more source

Use of fibrates is not associated with reduced risks of mortality or cardiovascular events among ESRD patients: A national cohort study

Frontiers in Cardiovascular Medicine, 2022
BackgroundAlthough a recent study reported that fibrates are associated with a low risk of cardiovascular (CV) death and can postpone the need for long-term hemodialysis in patients with advanced chronic kidney disease (CKD), little is known regarding ...
Wen-Yu Ho, Chieh-Li Yen, Chieh-Li Yen, Cheng-Chia Lee, Cheng-Chia Lee, Yi-Ran Tu, Yi-Ran Tu, Chao-Yu Chen, Chao-Yu Chen, Ching-Chung Hsiao, Ching-Chung Hsiao, Pao-Hsien Chu, Pao-Hsien Chu, Hsiang-Hao Hsu, Hsiang-Hao Hsu, Ya-Chun Tian, Ya-Chun Tian, Chih-Hsiang Chang, Chih-Hsiang Chang   +18 more
doaj   +1 more source